Why the study?
Does BR96-doxorubicin conjugate improve antitumor activity compared to doxorubicin in patients with metastatic breast cancer expressing Lewis-Y antigen?
Population
23 assessable patients with measurable metastatic breast cancer and immunohistochemical evidence of Lewis-Y…
Comparison
BR96-doxorubicin conjugate 700 mg/m2 IV over 24… vs Doxorubicin 60 mg/m2 every 3 weeks
Design
RCT, Stratified on the basis of prior doxorubicin exposure, visceral disease…
Authors
Loading...
BR96-doxorubicin conjugate yields inferior responses plus prominent GI toxicity versus doxorubicin; challenges its further development in Lewis-Y–positive metastatic breast cancer.
Does BR96-doxorubicin conjugate improve antitumor activity compared to doxorubicin in patients with metastatic breast cancer expressing Lewis-Y antigen?
The BR96-doxorubicin immunoconjugate demonstrated limited clinical antitumor activity and prominent gastrointestinal toxicity compared to standard doxorubicin in metastatic breast cancer.
Tolcher et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: